RxDoctor Payments Data

Walter Ventayen, MD

Internal Medicine · Lamont, CANPI 1841303286

Payments from drug & device makers

$1,182in general payments, 2019–2025

Across 58 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$298
  • Novo Nordisk$277
  • Boehringer Ingelheim$125
  • GSK$118
  • Lilly USA, LLC$110
  • Bayer$108
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$1,182100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,182 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$3,760
Medicare patients
16
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin256$292,524
OzempicSemaglutide194$198,972
TrulicityDulaglutide184$191,893
TradjentaLinagliptin120$116,099
JanuviaSitagliptin Phosphate77$85,304
FarxigaDapagliflozin Propanediol50$62,109
MounjaroTirzepatide52$61,441
Trelegy ElliptaFluticasone/Umeclidin/Vilanter82$56,761
EliquisApixaban74$56,674
Tresiba Flextouch U-100Insulin Degludec145$52,504
Breo ElliptaFluticasone/Vilanterol91$38,824
XareltoRivaroxaban30$34,207
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr63$30,253
CreonLipase/Protease/Amylase12$18,675
Tresiba Flextouch U-200Insulin Degludec17$15,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$125$408,624376 claims
Lilly USA, LLCTrulicity, Mounjaro$110$253,334236 claims
Novo NordiskOzempic, Rybelsus$277$211,359205 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$118$125,838236 claims
MerckJanuvia$45$85,30477 claims
AstraZenecaFarxiga, Symbicort$298$67,20170 claims
PfizerEliquis$16$56,67474 claims
Johnson & JohnsonXarelto$36$34,20730 claims
AbbVieCreon, Linzess$20$31,55132 claims
NovartisEntresto$17$15,34412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lamont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →